Atopic dermatitis (AD) is a chronic inflammatory skin disease driven by type 2 inflammation, with prevalence rates of 15–25% in children and 3–7% in adults worldwide. At present, the treatment of Atopic dermatitis includes basic moisturization, topical agents, phototherapy, systemic medications, and targeted therapies.
For mild Atopic dermatitis, moisturizers, topical corticosteroids, or calcineurin inhibitors are commonly used. For moderate-to-severe cases, phototherapy and conventional systemic immunosuppressants are utilized. In recent years, targeted therapies, such as dupilumab and Janus Kinase (JAK) inhibitors, have revolutionized the management of moderate-to-severe Atopic dermatitis, demonstrating significant efficacy and improved safety profiles compared with traditional immunosuppressant. Head and neck atopic dermatitis (HNAD) is a clinically common subtype of Atopic dermatitis. While dupilumab is widely used in Atopic dermatitis treatment, its efficacy in Head and neck atopic dermatitis is debatable. This study aimed to evaluate the real-world efficacy and safety of dupilumab in Head and neck atopic dermatitis.
A retrospective study included 29 individuals with Head and neck atopic dermatitis (17 adults and 12 pediatric patients) who were treated with dupilumab. Primary variables, including the Eczema Area and Severity Index (EASI), the Dermatology Life Quality Index (DLQI), Investigator’s Global Assessment (IGA), Patient-Oriented Eczema Measure (POEM), Visual Analog Scale for Itch (VAS-Itch), and Visual Analog Scale for Sleep Quality (VAS-SQ), were evaluated at baseline, week 4, week 8, and week 16. Data on adverse events (AEs) were routinely collected.
Results: At week 16, all assessments demonstrated improvement. Both groups exhibited significant decreases (p < 0.05) in efficacy indicators, with the exception of children’s DLQI, which showed a decreasing trend but did not achieve statistical significance. These findings indicate that dupilumab significantly decreased the severity of the condition and improved the overall quality of life in both adults and children. This real-world study revealed that dupilumab could be an effective and safe therapy for Head and neck atopic dermatitis patients across both children and adults.
Reference:
Li Z, Peng J, Yu R, Lin Y. Real-world efficacy and safety of dupilumab in the treatment of head and neck atopic dermatitis: a retrospective cohort study. Front Med (Lausanne). 2025 Nov 27;12:1705374. doi: 10.3389/fmed.2025.1705374. PMID: 41393119; PMCID: PMC12695528.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.